For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com.

Documented progression from most recent line of therapy

1-3 prior lines of therapy

Measurable disease

Life expectancy ≥3 months

Prior treatment with Lenalidomide permitted if:

1. Best response achieved was ≥Partial Response (PR)

2. Patient was not refractory

3. Patient did not discontinue due to a Grade ≥3 related adverse event

4. Subject did not receive more than 9 cycles of Lenalidomide and had at least 9 months between the last dose of Lenalidomide and progression

Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Relapsed or Refractory Multiple Myeloma